Copyright © Inderes 2011 - present. All rights reserved.
Analytikerkommentar

Egoo Health prepares to enter the US market

Qlife Holding

Egoo Health prepares to enter the US market!

Qlife recently participated in the leading industry conference, AACC Annual Scientific Meeting & Clinical Lab Expo in Anaheim to present the company and its key offerings for the portable point of care clinical biomarker and virus testing market, as well as launching its new Egoo Innovate system. The leading New York based biology research company 360Dx interviewed Qlife at the conference who was represented by CEO Thomas Warthoe and Director of R&D Maiken Rosenstierne as well as CFO Kasper Boel Rousøe and Marketing Manager Christopher Lee Dahm. The management team presented the go to market commercialization strategy and the technical benefits and capabilities of its Egoo Device system to perform multiple tests and sample types, currently focusing on testing for C-reactive protein levels following rising inflammation or CRP.

According to Maiken Rosenstierne, Qlife is currently developing other tests, the primary ones being testing for vitamin D, HbA1c and lipid levels. Parallel to broaden the number of tests available on the Egoo Device system, Qlife is also working on increasing the number of customer types, as they hope to soon be able to finalize the required IVDR regulatory CE-mark protocols to include at-home use to complement the professional use for which it currently has approval. As Qlife is still in proceedings to receive regulatory approval according to Europe’s In Vitro Diagnostic Regulations, the Egoo Device is primarily sold to the professional wellness segment.

As mentioned above, the conference participation also marked the launch of Qlifes latest attempt to accelerate the awareness and use of the Egoo System by launching the open sourced based Egoo Innovate. According to Christopher Lee Dahm, the ambition of the Egoo Innovate system is to let partners work decentralized in the system to create and optimize an assay for specific biomarkers of their own choosing.

Additionally, the Innovate system platform can help partners design assays for use in clinical trials. According to Thomas Warthoe, Qlife has already ‘seen interest from pharmaceutical companies to develop tests to monitor the safety and efficacy of drugs in clinical trials, and the firm is in discussions with undisclosed pharmaceutical partners to develop companion diagnostic tests.’

Watch this video where CEO Thomas Warthoe demonstrates The Egoo Health platform and talk about the market - this interview is 42 min long:

https://www.inderes.dk/videos/qlife-holding-introduction-to-market-segment-and-demonstration-of-egoo

Disclaimer:

HC Andersen Capital receives payment from Qlife for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 6:55 AM 23-08-2023.

Qlife Holding AB er et medico teknisk selskab, der stræber efter at revolutionere markedet for kliniske biomarkør- og virustest. Ved at muliggøre test derhjemme som et supplement til test i sundhedssystemet, lettes adgang til vigtige sundhedsinformationer, hvilket kan bidrage til bedre behandling og potentielt forebygge sygdomme. De første testkapsler i virksomhedens brand, Egoo. Health Platform, blev CE-mærket til professionelt brug i begyndelsen af 2020. Virksomheden har patentbeskyttelse for centrale dele af sin teknologi. Det danske selskab er noteret på Nasdaq First North Stockholm.

Læs mere på virksomhedsside
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.